<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Naltrexone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Naltrexone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Naltrexone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10889" href="/d/html/10889.html" rel="external">see "Naltrexone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F199546"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vivitrol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867639"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Naltrexone;</li>
<li>ReVia</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F199577"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Opioid Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F199550"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Do not initiate therapy until patient has passed a naloxone challenge test or is opioid-free (including tramadol) for at least 7 to 10 days after last opioid use; up to 14 days may be necessary for patients on long-acting opioids (eg, methadone, buprenorphine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMHSA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMHSA.2022'])">Ref</a></span>). If need for opioid pain management is anticipated during treatment (eg, for elective surgery), discontinue oral naltrexone ≥3 days prior to surgery or IM naltrexone ≥30 days prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9192803-8b96-41ab-8488-f36d16324eb4">Alcohol use disorder, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol use disorder, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for patients currently taking opioids or with acute hepatitis, liver enzymes ≥3 to 5 times normal, or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420'])">Ref</a></span>). May be initiated while the patient is actively drinking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15811981','lexi-content-ref-Holt.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15811981','lexi-content-ref-Holt.2022'])">Ref</a></span>). Some experts consider alternative therapy if goals are not met within 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 mg once daily; may increase to 100 mg once daily after 1 week based on response and tolerability. Some experts initiate with 25 mg once daily for several days before increasing to 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16670409','lexi-content-ref-29301420','lexi-content-ref-Holt.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16670409','lexi-content-ref-29301420','lexi-content-ref-Holt.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 380 mg once every 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8bf17584-f279-409e-972b-cfd2cee9068c">Opioid use disorder, mild to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid use disorder, mild to severe (alternative agent for moderate to severe):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Treatment initiation should be medically supervised due to risk for precipitated withdrawal. Some experts consider switching to alternative therapy if goals are not met within 3 to 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Strain.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Strain.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (alternative route): Initial: 25 mg once daily for 1 to 3 days; if no withdrawal signs occur, administer 50 mg once daily thereafter. <b>Note: </b>Use only for patients who are highly motivated or able to comply with techniques such as observed dosing to enhance adherence; efficacy is limited when patient adherence is poor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMHSA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMHSA.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM: </b>380 mg once every 4 weeks. <b>Note:</b> Patients who experience a reduction in efficacy prior to 4 weeks (eg, breakthrough cravings, ability to overcome opioid receptor blockade), may benefit from dosing every 3 weeks; however, no clinical trials have evaluated dosing frequencies &lt;4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching from buprenorphine to naltrexone</i>: Taper the buprenorphine dose gradually and discontinue. Wait 7 to 14 days before initiating treatment with naltrexone. A naloxone challenge may be used to demonstrate an absence of physical dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching from methadone to naltrexone:</i> Taper the methadone dose gradually and discontinue. Wait 7 to 14 days before initiating treatment with naltrexone. A naloxone challenge may be used to demonstrate an absence of physical dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching from naltrexone to methadone or buprenorphine:</i> Begin methadone or buprenorphine ~1 day following last dose of oral naltrexone and ~28 days following last dose of IM naltrexone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89d6bc99-18f1-46c6-acd4-c58717d97834">Pruritus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Opioid-induced, associated with neuraxial opioid administration:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 6 mg once; generally, doses &gt;6 mg may reverse analgesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2105673','lexi-content-ref-2205128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2105673','lexi-content-ref-2205128'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonopioid-induced (eg, from cholestasis) (alternative agent): Note: </b>Studies of naltrexone for uremic pruritus have mixed results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15178915','lexi-content-ref-10703675','lexi-content-ref-8950882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15178915','lexi-content-ref-10703675','lexi-content-ref-8950882'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 12.5 mg to 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30070375','lexi-content-ref-8633543','lexi-content-ref-12445410','lexi-content-ref-9322521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30070375','lexi-content-ref-8633543','lexi-content-ref-12445410','lexi-content-ref-9322521'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990842"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate-to-severe impairment: No dosage adjustment provided in manufacturer’s labeling (has not been studied); use with caution since naltrexone and its primary metabolite are primarily excreted in urine.</p></div>
<div class="block doha drugH1Div" id="F50988085"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: No dosage adjustment provided in manufacturer’s labeling (has not been studied); naltrexone AUC increased ~5- and 10-fold in patients with compensated or decompensated hepatic cirrhosis respectively. Use is not recommended in acute hepatitis or hepatic failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F199551"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55799609"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Accidental opioid overdose</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Naltrexone may result in accidental opioid overdose in patients with opioid dependence or opioid use disorder. Risk of opioid overdose with naltrexone use may be higher than other opioid agonist treatments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15049745','lexi-content-ref-17564876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15049745','lexi-content-ref-17564876'])">Ref</a></span>). Opioid overdose related to naltrexone use may result in life-threatening and fatal events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9179515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9179515'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; naltrexone is an opioid receptor-antagonist, reducing or blocking the effects of opioids and potentially leading to secondary up-regulation of opioid receptors. Patients may be hypersensitive to opioid effects and susceptible to overdose at lower opioid doses than previously tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15049745','lexi-content-ref-17564876','lexi-content-ref-12755943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15049745','lexi-content-ref-17564876','lexi-content-ref-12755943'])">Ref</a></span>). In addition, the opioid competitive receptor blockade produced by naltrexone is potentially surmountable in the presence of large amounts of opioids.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; overdose occurred within 2 weeks after discontinuation in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15049745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15049745'])">Ref</a></span>). In another study, overdose occurred within a 12-month period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9179515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9179515'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Naltrexone discontinuation</p>
<p style="text-indent:-2em;margin-left:6em;">• Missed doses of naltrexone</p>
<p style="text-indent:-2em;margin-left:6em;">• Near the end of the naltrexone dosing interval</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15049745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15049745'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Time since opioid administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15049745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15049745'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patient metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15049745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15049745'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Naltrexone may cause transient, mildly <b>increased serum transaminases</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9400350','lexi-content-ref-7983232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9400350','lexi-content-ref-7983232'])">Ref</a></span>). Most increases in serum transaminases resolve (some with continued therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9400350','lexi-content-ref-2303621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9400350','lexi-content-ref-2303621'])">Ref</a></span>). Hepatitis has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; exact mechanism unknown. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2871452','lexi-content-ref-2303621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2871452','lexi-content-ref-2303621'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most <b>increased serum alanine aminotransferase</b> and <b>increased serum aspartate aminotransferase</b> occur in the first 30 days of therapy, but may occur later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16614539','lexi-content-ref-21797892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16614539','lexi-content-ref-21797892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher oral doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16614539','lexi-content-ref-18241321']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16614539','lexi-content-ref-18241321'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16614539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16614539'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (&gt;50 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16614539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16614539'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Injection site reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Naltrexone IM administration may cause <b>injection site reaction</b>, <b>pain at injection site</b>, <b>tenderness at injection site</b>, <b>bruising at injection site</b>, <b>swelling at injection site,</b>
<b>injection site nodule,</b> and <b>itching at injection site</b>. Serious reactions, including <b>abscess at injection site</b>, <b>cellulitis at injection site</b>, <b>hematoma at injection site</b>, <b>induration at injection site</b>, <b>sterile abscess at injection site</b>, and <b>tissue necrosis at injection site</b> have been reported; some requiring surgical intervention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26820699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26820699'])">Ref</a></span>). Nicolau syndrome or embolia cutis medicamentosa has been reported, characterized by blanching and pain around the injection site, followed by erythema and tissue necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898411','lexi-content-ref-23242099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898411','lexi-content-ref-23242099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Most injection site reactions may be related to improper administration. Nicolau syndrome may occur due to direct damage to the end artery or cytotoxic effects of naltrexone and/or additives in the preparation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23242099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23242099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most injection site reactions occur within 1 to 3 days but may occur more than 10 days after injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26820699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26820699'])">Ref</a></span>). Nicolau syndrome may occur after 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26820699','lexi-content-ref-23242099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26820699','lexi-content-ref-23242099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Improper administration (eg, inadvertent SUBQ administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26820699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26820699'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26820699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26820699'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Naltrexone-precipitated opioid withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Naltrexone may precipitate <b>opioid withdrawal syndrome </b>in patients with opioid dependence or opioid use disorder. Symptoms may be severe and include abdominal pain, agitation, altered level of consciousness, confusion, diaphoresis, diarrhea, dilated pupils, dizziness, irritability, nausea, pain, tachycardia, and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18855831','lexi-content-ref-23690227','lexi-content-ref-12755943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18855831','lexi-content-ref-23690227','lexi-content-ref-12755943'])">Ref</a></span>). Naltrexone-precipitated opioid withdrawal symptoms may last 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23690227','lexi-content-ref-12755943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23690227','lexi-content-ref-12755943'])">Ref</a></span>). Withdrawal symptoms may require hospitalization but are rarely life-threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23690227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23690227'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; naltrexone displaces opioids from opioid receptors, precipitating withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12755943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12755943'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; within 5 minutes, peaking between 1 to 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23690227','lexi-content-ref-12755943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23690227','lexi-content-ref-12755943'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk Factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose and timing of opioid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18855831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18855831'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Naltrexone administration prior to adequate opioid-free period</p>
<p style="text-indent:-2em;margin-left:6em;">• Accidental or deliberate naltrexone administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23690227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23690227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Transitioning from methadone or buprenorphine to naltrexone</p>
<p style="text-indent:-2em;margin-left:6em;">• Peri-operative pain management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25612099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25612099'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F199520"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are as reported with the IM formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%), anorexia (≤14%), change in appetite (≤14%), decreased appetite (≤14%), diarrhea (13%), nausea (33%), vomiting (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (2% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Aspartate Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-aspartate-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-aspartate-aminotransferase')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Serum Aspartate Aminotransferase</span>, increased serum transaminases (20%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Transaminases table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-transaminases" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-transaminases')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Transaminases</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Aspartate Aminotransferase" frame="border" id="lexi-content-increased-serum-aspartate-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Increased Serum Aspartate Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Opioid dependence</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alcohol dependence</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Transaminases" frame="border" id="lexi-content-increased-serum-transaminases" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Increased Serum Transaminases</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Opioid dependence</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site (35%)<span class="lexi-table-link-container"> (<a aria-label="Induration at Injection Site table link" class="lexi-table-link" data-table-id="lexi-content-induration-at-injection-site" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-induration-at-injection-site')">table 3</a>)</span><span class="table-link" style="display:none;">Induration at Injection Site</span>, injection-site reaction (69%, including injection-site nodule and swelling at injection site)<span class="lexi-table-link-container"> (<a aria-label="Injection Site Reaction table link" class="lexi-table-link" data-table-id="lexi-content-injection-site-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-injection-site-reaction')">table 4</a>)</span><span class="table-link" style="display:none;">Injection Site Reaction</span>, pain at injection site (17%)<span class="lexi-table-link-container"> (<a aria-label="Pain at Injection Site table link" class="lexi-table-link" data-table-id="lexi-content-pain-at-injection-site" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pain-at-injection-site')">table 5</a>)</span><span class="table-link" style="display:none;">Pain at Injection Site</span>, tenderness at injection site (45%)<span class="lexi-table-link-container"> (<a aria-label="Tenderness at Injection Site table link" class="lexi-table-link" data-table-id="lexi-content-tenderness-at-injection-site" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tenderness-at-injection-site')">table 6</a>)</span><span class="table-link" style="display:none;">Tenderness at Injection Site</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Induration at Injection Site" frame="border" id="lexi-content-induration-at-injection-site" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Induration at Injection Site</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">380 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alcohol dependence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Injection Site Reaction" frame="border" id="lexi-content-injection-site-reaction" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Injection Site Reaction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">69%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">380 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alcohol dependence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pain at Injection Site" frame="border" id="lexi-content-pain-at-injection-site" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Pain at Injection Site</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">380 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alcohol dependence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tenderness at Injection Site" frame="border" id="lexi-content-tenderness-at-injection-site" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Tenderness at Injection Site</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">45%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">380 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alcohol dependence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (12%), asthenia (23%), dizziness (≤13%), headache (25%), insomnia (≤14%), sleep disorder (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤12%), arthritis (≤12%), increased creatine phosphokinase in blood specimen (11% to 39%), joint stiffness (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (7%)<span class="lexi-table-link-container"> (<a aria-label="Bruising at Injection Site table link" class="lexi-table-link" data-table-id="lexi-content-bruising-at-injection-site" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bruising-at-injection-site')">table 7</a>)</span><span class="table-link" style="display:none;">Bruising at Injection Site</span>, injection-site pruritus (10%)<span class="lexi-table-link-container"> (<a aria-label="Injection-Site Pruritus table link" class="lexi-table-link" data-table-id="lexi-content-injection-site-pruritus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-injection-site-pruritus')">table 8</a>)</span><span class="table-link" style="display:none;">Injection-Site Pruritus</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bruising at Injection Site" frame="border" id="lexi-content-bruising-at-injection-site" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Bruising at Injection Site</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">380 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alcohol dependence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Injection-Site Pruritus" frame="border" id="lexi-content-injection-site-pruritus" rules="all">
<caption style="text-align:center;">
<b>Naltrexone: Adverse Reaction: Injection-Site Pruritus</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Naltrexone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">380 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alcohol dependence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (8% to 10%), drowsiness (≤4%), sedated state (≤4%), suicidal ideation (≤1%), suicidal tendencies (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (≤6%), back stiffness (≤6%), muscle cramps (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: , Angina pectoris, atrial fibrillation, chest pain, chest tightness, coronary artery disease, deep vein thrombosis, heart failure, palpitations, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, night sweats, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, dehydration, heat exhaustion, hot flash, hypercholesterolemia, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, cholecystitis, cholelithiasis, colitis, constipation, dysgeusia, flatulence, gastroenteritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, hemorrhoids, increased appetite, paralytic ileus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet count, eosinophilia, leukocytosis, lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, acute ischemic stroke, agitation, alcohol withdrawal syndrome, cerebral aneurysm, chills, decreased mental acuity, disturbance in attention, euphoria, irritability, lethargy, migraine, paresthesia, rigors, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain, muscle spasm, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, chronic obstructive pulmonary disease, dyspnea, laryngitis, nasal congestion, pharyngolaryngeal pain, sinusitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Gubitosa 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (Verma 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased serum alanine aminotransferase (Sax 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site, cellulitis at injection site, hematoma at injection site, sterile abscess at injection site, tissue necrosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium (Gowing 2017), opioid withdrawal syndrome (Hassanian-Moghaddam 2014; Yeo 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (Gastfriend 2011), pneumonia (including interstitial pneumonia) (Gastfriend 2011)</p></div>
<div class="block coi drugH1Div" id="F199533"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to naltrexone or any component of the formulation; current physiological opioid dependence or current use of opioid analgesics (including partial opioid agonists); acute opioid withdrawal; failure to pass naloxone challenge or positive urine screen for opioids</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Acute hepatitis; hepatic failure</p></div>
<div class="block war drugH1Div" id="F199517"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal thoughts/depression: Suicidal thoughts, attempted suicide, and depression have been reported postmarketing; monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use IM injection with caution in patients thrombocytopenia or any bleeding disorder (including hemophilia and severe hepatic failure), or patients on anticoagulant therapy; bleeding/hematoma may occur from IM administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in acute hepatitis or hepatic failure (APA [Reus 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with moderate to severe renal impairment (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Vehicle used in the injectable naltrexone formulation (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis following injection of other drug products that also use the polylactide-co-glycolide microspheres vehicle.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: There is no maximum recommended duration for maintenance treatment of opioid use disorder; patients may require treatment indefinitely. Advise patients of the potential to relapse to illicit drug use following discontinuation of opioid use disorder treatment (SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Opioid use disorder: Patients should be opioid-free (including tramadol) for a minimum of 7 to 10 days; a naloxone challenge test may be helpful to confirm patient is opioid-free prior to therapy if there is any suspicion since urinary opioid screen may not be sufficient proof. Patients transitioning from buprenorphine or methadone may be vulnerable to precipitation of withdrawal symptoms for as long as 2 weeks. Use of naltrexone does not eliminate or diminish withdrawal symptoms. Oral naltrexone tablets have not been shown to be more effective than placebo for opioid use disorder due to poor patient adherence (SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Emergency pain management: In naltrexone-treated patients requiring emergency pain management, consider alternatives to opioid therapy (eg, regional analgesia, nonopioid analgesics, general anesthesia). If opioid therapy is required for pain therapy, patients should be under the direct care of a trained anesthesia provider.</p>
<p style="text-indent:-2em;margin-left:4em;">• Naloxone access: Discuss the availability of naloxone with all patients, as well as their caregivers, at initial treatment and regularly during therapy (eg, with each subsequent naltrexone injection). Patients being treated for an opioid use disorder have the potential for relapse and are at risk for opioid overdose; this risk may be increased in patients treated with naltrexone near the end of the naltrexone dosing interval (particularly if using naltrexone injection), if a dose of naltrexone is missed, or when naltrexone treatment is discontinued. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: In patients treated with naltrexone for opioid use disorder who are requiring surgery, discontinue oral naltrexone at least 72 hours before scheduled elective surgery if opioid use is anticipated; extended-release IM naltrexone should be discontinued at least 30 days prior to scheduled surgery (oral naltrexone may be used temporarily) (ASAM 2020).</p></div>
<div class="block foc drugH1Div" id="F199527"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vivitrol: 380 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block geq drugH1Div" id="F199513"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F199535"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Vivitrol Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">380 mg (per each): $1,969.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Naltrexone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.14 - $4.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867640"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ReVia: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block adm drugH1Div" id="F199530"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered with or without food. Administration with food or after meals may minimize adverse gastrointestinal effects. Advise patient not to self-administer opioids while receiving naltrexone therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Vivitrol: Administer deep IM into the gluteal muscle; must inject dose using one of the provided needles for administration. Use either the 1.5-inch needle (for very lean patients) or the 2-inch needle (for patients with a larger amount of subcutaneous tissue overlying the gluteal muscle). Either needle may be used for patients with average body habitus. Avoid inadvertent injection into a blood vessel; do not administer IV, SUBQ, or into fatty tissue (the risk of serious injection site reaction is increased if given incorrectly as a SUBQ injection or into fatty tissue instead of the gluteal muscle). Injection should alternate between the 2 buttocks. Do not substitute any components of the dose-pack.</p></div>
<div class="block meg drugH1Div" id="F10120352"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Vivitrol: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F021897s052lbl.pdf%23page%3D33&amp;token=dmfJbnG2ixudS%2F7AFtC9PWKmc59sD3Sb3tTGF9kC584fhQDVnYZTE493gDDDwVrwav6k2nPE561CoZXHiO6YD%2B9ROND2KtrImvry9cRvjit9tHKFqqBdotp%2Bmc7R6wSO&amp;TOPIC_ID=9679" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021897s052lbl.pdf#page=33</a></p></div>
<div class="block use drugH1Div" id="F199528"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol use disorder: </b>Treatment of alcohol use disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid use disorder, mild to severe:</b> For the blockade of the effects of exogenously administered opioids.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Limitation of use: </i>Oral naltrexone tablets have not been shown to be more effective than placebo for opioid use disorder due to poor patient adherence (SAMHSA 2021).</p></div>
<div class="block off-label drugH1Div" id="F26524985"><span class="drugH1">Use: Off-Label: Adult</span><p>Pruritus</p></div>
<div class="block mst drugH1Div" id="F199585"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Naltrexone may be confused with methylnaltrexone, naloxone</p>
<p style="text-indent:-2em;margin-left:4em;">ReVia may be confused with Revatio</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vivitrol: For deep intramuscular (IM) gluteal injection only</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299740"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F199522"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bremelanotide: May decrease the serum concentration of Naltrexone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May decrease the serum concentration of Naltrexone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylnaltrexone: May enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: Opioid Antagonists may enhance the adverse/toxic effect of Naldemedine. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: Opioid Antagonists may enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Naltrexone may diminish the therapeutic effect of Opioid Agonists.  Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sibutramine: May enhance the adverse/toxic effect of Centrally Acting Weight Loss Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54091340"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Naltrexone is not the preferred treatment for opioid use disorder during pregnancy; pregnancy testing is recommended prior to initiating naltrexone therapy (SAMHSA 2021).</p></div>
<div class="block pri drugH1Div" id="F2914152"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Naltrexone and the 6-beta-naltrexol metabolite cross the placenta (Towers 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Alcohol use and opioid use disorder are associated with adverse fetal and obstetrical outcomes. Information related to the use of naltrexone during pregnancy is limited (ACOG 711 2017; Farid 2008; Towers 2020; Tran 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of naltrexone for the treatment of opioid use disorder during pregnancy is limited. Consider transitioning to a preferred agent or discontinue treatment if the patient and health care provider agree the risk of relapse is low. If treatment with naltrexone continues, the risks and benefits should be discussed (ASAM 2020; SAMHSA 2021). Pregnant patients are not appropriate candidates for the ER injection (SAMHSA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Pharmacological agents should not be used for the treatment of alcohol use disorder in pregnant patients unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder; agents other than naltrexone are recommended for acute alcohol withdrawal (APA [Reus 2018]).</p></div>
<div class="block brc drugH1Div" id="F20616465"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone and the 6-beta-naltrexol metabolite are present in breast milk (Chan 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Pharmacological agents should not be used for the treatment of alcohol use disorder in breastfeeding patients unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder; agents other than naltrexone are recommended for acute alcohol withdrawal (APA [Reus 2018]).</p></div>
<div class="block mop drugH1Div" id="F199525"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function tests (baseline and periodic); signs or symptoms of opioid withdrawal, injection-site reactions with IM administration; pregnancy test (baseline); hepatitis and HIV testing, particularly for patients with opioid use disorder (prior to initiation) (SAMHSA 2021); and depression and/or suicidal thinking</p></div>
<div class="block pha drugH1Div" id="F199516"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Naltrexone (a pure opioid antagonist) is a cyclopropyl derivative of oxymorphone similar in structure to naloxone and nalorphine (a morphine derivative); it acts as a competitive antagonist at opioid receptor sites, showing the highest affinity for mu receptors. Endogenous opioids are involved in modulating the expression of alcohol's reinforcing effects (Hemby 1997; Lee 2005). Naltrexone also modifies the hypothalamic-pituitary-adrenal axis to suppress alcohol consumption (Williams 2004).</p></div>
<div class="block phk drugH1Div" id="F199532"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: 50 mg: 24 hours; 100 mg: 48 hours; 150 mg: 72 hours; IM: 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Almost complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~1350 L; widely throughout the body but considerable interindividual variation exists</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively metabolized via noncytochrome-mediated dehydrogenase conversion to 6-beta-naltrexol (primary metabolite) and related minor metabolites; glucuronide conjugates are also formed from naltrexone and its metabolites</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Extensive first-pass effect</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 21%</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Variable range (5% to 40%)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral: 4 hours; 6-beta-naltrexol: 13 hours; IM: Naltrexone and 6-beta-naltrexol: 5 to 10 days (dependent upon erosion of polymer)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: ~60 minutes; IM: Biphasic: ~2 hours (first peak), ~2 to 3 days (second peak)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (as metabolites and small amounts of unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51159720"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: An increase in naltrexone AUC of approximately 5- and 10-fold in patients with compensated and decompensated liver cirrhosis, respectively, compared with subjects with healthy liver function has been reported.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F199536"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nalcotrex | Revez</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dependex | Ethylex | Naltrexin | Naltrexon accord | Naltrexon hexal pharma | Nemexin | Revia</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo naltrexone | Naltrexone QP | Revia</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Naltrax | Nodict</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nalorex | Naltrexone accord</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Revia</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Revia | Uninaltrex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nemexin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nalerona</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Naltrexone | Narcoral | Nuo xin sheng</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Naltrexone aop | Revia</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Nalorex | Naltrexon HCl aop | Naltrexonhydrochlorid accord | Nemexin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Naltima</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Naltrexone accord | Naltrexone aop | Nodict | Revia</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Anarcol | Deltrexone | Nerquon | Revia | Trexone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Celupan | Naltrexona accord | Revia | Tranalex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Naltrexon vitaflo | Naltrexone accord | Naltrexone POA Pharma | Revia</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nalorex | Naltrexone Intas | Naltrexone Serb | Revia</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Nalorex | Naltrexone accord | Naltrexone aop | Opizone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Nalorex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Naltrexone HCl L. Molteni | Revia | Trexan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Nemexin | Revia</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Nutrexon | Phaltrexia | Revia</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ethylex | Nalorex | Naltrexone | Revia</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Revia</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Addtrex | Nalcon | Naltima | Naltivive | Naltox | Nodict</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nalorex | Naltrexone Accord Healthcare | Narcoral</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Revia</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Addtrex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hulexone | I rexone | Mislim | Naltra | Naltrexin | Naltrexone | Narex | Pharma naltrexone | Revia | Traxone | Wi naltrexone</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Revia</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Nalorex | Naltrexone | Naltrexone accord | Revia</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Naltrexone | Naltrexone accord | Revia</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Arrop | Revia</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Naltrexone | Narpan | Revia | Trexan</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Lodonal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nalorex | Naltrexon | Naltrexon hydrochloride accord | Naltrexonhydrochloride pch | Revia</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Nalorex | Naltrexon | Naltrexon accord | Naltrexone accord | Naltrexone poa | Revia</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Naltraccord | Revia</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Nalerona</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Trexan | Zalter</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Nalorex | Naltex | Naltrexone hydrochloride Accord | Nemexin | Revia | Vivitrol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Naltrexone HCL | Revia</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Basinal | Destoxican | Nalorex | Naltrexona accord | Naltrexona wynn</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Nalerona</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Adepend</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Revia</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Naltrexone | Revia | Vivitrol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Naltrexon | Naltrexon abcur | Naltrexone accord | Naltrexone POA Pharma | Revia</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Narpan | Revia | Trexan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Adepend | Revia</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adepend</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Revia</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ethylex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Revia</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Naltima | Naltrex | Naltrexin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Regental | Servixone</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Naltrexin | Naltrexone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Naltima | Revia</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2105673">
<a name="2105673"></a>Abboud TK, Afrasiabi A, Davidson J, et al. Prophylactic oral naltrexone with epidural morphine: effect on adverse reactions and ventilatory responses to carbon dioxide. <i>Anesthesiology</i>. 1990a;72(2):233-237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/2105673/pubmed" id="2105673" target="_blank">2105673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2205128">
<a name="2205128"></a>Abboud TK, Lee K, Zhu J, et al. Prophylactic oral naltrexone with intrathecal morphine for cesarean section: effects on adverse reactions and analgesia. <i>Anesth Analg</i>. 1990b;71(4):367-370. doi:10.1213/00000539-199010000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/2205128/pubmed" id="2205128" target="_blank">2205128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26820699">
<a name="26820699"></a>Ahamad K, Korthuis PT, Lum PJ, Johnson C, Wood E. A delayed injection-site reaction in a patient receiving extended-release naltrexone. <i>Subst Abus</i>. 2016;37(2):278-280. doi:10.1080/08897077.2016.1138919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/26820699/pubmed" id="26820699" target="_blank">26820699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742676">
<a name="28742676"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion No. 711: opioid use and opioid use disorder in pregnancy. <i>Obstet Gynecol</i>. 2017;130(2):e81-e94. doi:10.1097/AOG.0000000000002235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/28742676/pubmed" id="28742676" target="_blank">28742676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511106">
<a name="32511106"></a>American Society of Addiction Medicine (ASAM). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. <i>J Addict Med</i>. 2020;14(2S)(suppl 1):1‐91. doi:10.1097/ADM.0000000000000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/32511106/pubmed" id="32511106" target="_blank">32511106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16670409">
<a name="16670409"></a>Anton RF, O'Malley SS, Ciraulo DA, et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. <i>JAMA</i>. 2006;295(17):2003-2017. doi:10.1001/jama.295.17.2003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/16670409/pubmed" id="16670409" target="_blank">16670409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8633543">
<a name="8633543"></a>Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. <i>Am J Gastroenterol</i>. 1996;91(5):1022-1023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/8633543/pubmed" id="8633543" target="_blank">8633543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15296587">
<a name="15296587"></a>Chan CF, Page-Sharp M, Kristensen JH, O'Neil G, Ilett KF. Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milk. <i>J Hum Lact</i>. 2004;20(3):322-326. doi:10.1177/0890334404266881.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/15296587/pubmed" id="15296587" target="_blank">15296587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9400350">
<a name="9400350"></a>Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. <i>Arch Gen Psychiatry</i>. 1997;54(12):1130-1135. doi:10.1001/archpsyc.1997.01830240090013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/9400350/pubmed" id="9400350" target="_blank">9400350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25612099">
<a name="25612099"></a>Curatolo C, Trinh M. Challenges in the perioperative management of the patient receiving extended-release naltrexone. <i>A A Case Rep</i>. 2014;3(11):142-144. doi:10.1213/XAA.0000000000000069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/25612099/pubmed" id="25612099" target="_blank">25612099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15049745">
<a name="15049745"></a>Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP; NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) [published correction appears in <i>Addiction</i>. 2005;100(1):139]. <i>Addiction</i>. 2004;99(4):450-460. doi:10.1111/j.1360-0443.2004.00654.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/15049745/pubmed" id="15049745" target="_blank">15049745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19305793">
<a name="19305793"></a>Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. <i>Curr Neuropharmacol</i>. 2008;6(2):125-150. doi:10.2174/157015908784533842.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/19305793/pubmed" id="19305793" target="_blank">19305793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18855831">
<a name="18855831"></a>Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. <i>Addiction</i>. 2008;103(8):1399-1401. doi:10.1111/j.1360-0443.2008.02252.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/18855831/pubmed" id="18855831" target="_blank">18855831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15811981">
<a name="15811981"></a>Garbutt JC, Kranzler HR, O'Malley SS, et al; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. <i>JAMA</i>. 2005;293(13):1617-1625. doi:10.1001/jama.293.13.1617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/15811981/pubmed" id="15811981" target="_blank">15811981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21272018">
<a name="21272018"></a>Gastfriend DR. Intramuscular extended-release naltrexone: current evidence. <i>Ann N Y Acad Sci</i>. 2011;1216:144-166. doi:10.1111/j.1749-6632.2010.05900.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/21272018/pubmed" id="21272018" target="_blank">21272018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17564876">
<a name="17564876"></a>Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. <i>Drug Alcohol Rev</i>. 2007;26(4):405-410. doi:10.1080/09595230701373834<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/17564876/pubmed" id="17564876" target="_blank">17564876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28553701">
<a name="28553701"></a>Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation for opioid withdrawal. <i>Cochrane Database Syst Rev</i>. 2017;5(5):CD002021. doi:10.1002/14651858.CD002021.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/28553701/pubmed" id="28553701" target="_blank">28553701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33269129">
<a name="33269129"></a>Gubitosa JC, Terwillliger T, Ukazu A, Gordon E. Naltrexone-associated non-ST-elevated myocardial infarction. <i>Cureus</i>. 2020;12(10):e11198. doi:10.7759/cureus.11198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/33269129/pubmed" id="33269129" target="_blank">33269129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23690227">
<a name="23690227"></a>Hassanian-Moghaddam H, Afzali S, Pooya A. Withdrawal syndrome caused by naltrexone in opioid abusers. <i>Hum Exp Toxicol</i>. 2014;33(6):561-567. doi:10.1177/0960327112450901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/23690227/pubmed" id="23690227" target="_blank">23690227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hemby.1997">
<a name="Hemby.1997"></a>Hemby SE, Johnson BA, Dworkin SI. Neurobiological basis of drug reinforcement. In: Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior. Johnson BA, Roache JD (Eds). Philadelphia, PA: Lippincott-Raven; 1997:137.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.2022">
<a name="Holt.2022"></a>Holt SR. Alcohol use disorder: pharmacologic management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16614539">
<a name="16614539"></a>Kim SW, Grant JE, Yoon G, Williams KA, Remmel RP. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. <i>Clin Neuropharmacol</i>. 2006;29(2):77-79. doi:10.1097/00002826-200603000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/16614539/pubmed" id="16614539" target="_blank">16614539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15897221">
<a name="15897221"></a>Lee YK, Park SW, Kim YK, et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. <i>Alcohol Alcohol</i>. 2005;40(4):297-301. doi:10.1093/alcalc/agh163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/15897221/pubmed" id="15897221" target="_blank">15897221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15178915">
<a name="15178915"></a>Legroux-Crespel E, Clèdes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. <i>Dermatology</i>. 2004;208(4):326-330. doi:10.1159/000077841<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/15178915/pubmed" id="15178915" target="_blank">15178915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30070375">
<a name="30070375"></a>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2019;69(1):394-419. doi:10.1002/hep.30145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/30070375/pubmed" id="30070375" target="_blank">30070375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19554543">
<a name="19554543"></a>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. <i>Hepatology</i>. 2009;50(1):291-308. doi:10.1002/hep.22906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/19554543/pubmed" id="19554543" target="_blank">19554543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18241321">
<a name="18241321"></a>Lucey MR, Silverman BL, Illeperuma A, O'Brien CP. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. <i>Alcohol Clin Exp Res</i>. 2008;32(3):498-504. doi:10.1111/j.1530-0277.2007.00593.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/18241321/pubmed" id="18241321" target="_blank">18241321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32898411">
<a name="32898411"></a>Malik MH, Heaton H, Sloan B. Nicolau syndrome following intramuscular naltrexone injection. <i>Dermatol Online J</i>. 2020;26(7):13030/qt3gb5m0vr.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/32898411/pubmed" id="32898411" target="_blank">32898411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9179515">
<a name="9179515"></a>Miotto K, McCann MJ, Rawson RA, Frosch D, Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. <i>Drug Alcohol Depend</i>. 1997;45(1-2):131-134. doi:10.1016/s0376-8716(97)01348-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/9179515/pubmed" id="9179515" target="_blank">9179515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2871452">
<a name="2871452"></a>Mitchell JE. Naltrexone and hepatotoxicity. <i>Lancet</i>. 1986;1(8491):1215. doi:10.1016/s0140-6736(86)91196-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/2871452/pubmed" id="2871452" target="_blank">2871452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2303621">
<a name="2303621"></a>Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. <i>J Stud Alcohol Drugs</i>. 2012;73(6):991-997. doi:10.15288/jsad.2012.73.991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/2303621/pubmed" id="2303621" target="_blank">2303621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30068260">
<a name="30068260"></a>Molero Y, Zetterqvist J, Binswanger IA, Hellner C, Larsson H, Fazel S. Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime. <i>Am J Psychiatry</i>. 2018;175(10):970-978. doi:10.1176/appi.ajp.2018.17101112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/30068260/pubmed" id="30068260" target="_blank">30068260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chartwell.1">
<a name="Chartwell.1"></a>Naltrexone hydrochloride tablets, USP [prescribing information]. Congers, NY: Chartwell Rx LLC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10703675">
<a name="10703675"></a>Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. <i>J Am Soc Nephrol</i>. 2000;11(3):514-519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/10703675/pubmed" id="10703675" target="_blank">10703675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8950882">
<a name="8950882"></a>Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. <i>Lancet</i>. 1996;348(9041):1552-1554. doi:10.1016/s0140-6736(96)04176-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/8950882/pubmed" id="8950882" target="_blank">8950882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23242099">
<a name="23242099"></a>Perli D, Martone C, Rapose A. Naltrexone-induced Nicolau syndrome masquerading as cutaneous abscess. <i>BMJ Case Rep</i>. 2012;2012:bcr2012007785. doi:10.1136/bcr-2012-007785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/23242099/pubmed" id="23242099" target="_blank">23242099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301420">
<a name="29301420"></a>Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. <i>Am J Psychiatry</i>. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/29301420/pubmed" id="29301420" target="_blank">29301420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Revia.1">
<a name="Revia.1"></a>Revia (naltrexone) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; April 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7983232">
<a name="7983232"></a>Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. <i>J Clin Pharmacol</i>. 1994;34(9):898-901. doi:10.1002/j.1552-4604.1994.tb04002.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/7983232/pubmed" id="7983232" target="_blank">7983232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strain.2022">
<a name="Strain.2022"></a>Strain E. Pharmacotherapy for opioid use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SAMHSA.2022">
<a name="SAMHSA.2022"></a>Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP21-02-01-002. Substance Abuse and Mental Health Services Administration; 2021. <a href="https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002" target="_blank">https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002</a>. Accessed February 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12445410">
<a name="12445410"></a>Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. <i>J Hepatol</i>. 2002;37(6):717-722. doi:10.1016/s0168-8278(02)00318-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/12445410/pubmed" id="12445410" target="_blank">12445410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21797892">
<a name="21797892"></a>Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. <i>Alcohol Clin Exp Res</i>. 2012;36(2):318-324. doi:10.1111/j.1530-0277.2011.01601.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/21797892/pubmed" id="21797892" target="_blank">21797892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31376396">
<a name="31376396"></a>Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. <i>Am J Obstet Gynecol</i>. 2020;222(1):83.e1-83.e8. doi:10.1016/j.ajog.2019.07.037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/31376396/pubmed" id="31376396" target="_blank">31376396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543191">
<a name="28543191"></a>Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ. Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. <i>Pharmacotherapy</i>. 2017;37(7):824-839. doi:10.1002/phar.1958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/28543191/pubmed" id="28543191" target="_blank">28543191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27922226">
<a name="27922226"></a>Verma R. Naltrexone-associated acute pancreatitis. <i>Prim Care Companion CNS Disord</i>. 2016;18(6):10.4088/PCC.16l01953. doi:10.4088/PCC.16l01953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/27922226/pubmed" id="27922226" target="_blank">27922226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vivitrol.1">
<a name="Vivitrol.1"></a>Vivitrol (naltrexone) [prescribing information]. Waltham, MA: Alkermes Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15100607">
<a name="15100607"></a>Williams KL, Broadbear JH, Woods JH. Noncontingent and response-contingent intravenous ethanol attenuates the effect of naltrexone on hypothalamic-pituitary-adrenal activity in rhesus monkeys. <i>Alcohol Clin Exp Res</i>. 2004;28(4):566-571.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/15100607/pubmed" id="15100607" target="_blank">15100607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9322521">
<a name="9322521"></a>Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. <i>Gastroenterology</i>. 1997;113(4):1264-1269. doi:10.1053/gast.1997.v113.pm9322521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/9322521/pubmed" id="9322521" target="_blank">9322521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12755943">
<a name="12755943"></a>Yeo M, Campbell V, Bonomo Y, Sawyer SM. Acute opioid withdrawal on accidental injection of naltrexone. <i>J Paediatr Child Health</i>. 2003;39(4):315-317. doi:10.1046/j.1440-1754.2003.00143.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naltrexone-drug-information/abstract-text/12755943/pubmed" id="12755943" target="_blank">12755943</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9679 Version 282.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
